Validea's pick of the week provides a detailed report on a company that scores well in the stock-screening service's model portfolios. On Validea.ca, investors can analyze 1,000 Canadian stocks through 12 different guru-based models and get individual reports on each company. Globe Investor provides marketing and data services to Validea.ca and receives compensation. Try it.
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt and the XenoSure biologic patch.
With a price/earnings ratio of 42.0 based on trailing 12-month earnings, this is not a value stock. However, earnings growth and other metrics are favoured by several of my guru-based investment strategies.
The Martin Zweig-based model favours LMAT's earnings growth rate of 40 per cent for the current quarter relative to the historical rate of 24.7 per cent. This model also likes the stock's persistent yearly earnings growth. The company's annual EPS growth rates before extraordinary items for the previous five years (from the earliest to the most recent year) were 0.13,. 0.16, 0.20, 0.23 and 0.42.
The stock is a strong relative performer, with relative strength at an exceptional level of 90. This metric is favoured by the Validea Momentum Investor model. That model also likes LMAT's industry (Medical Equipment and Supplies) as it is currently a top performer, based on the number of stocks making new 52-week highs.
My Motley Fool-inspired model favours LMAT's after-tax profit margin of 11.42 per cent, above the 7 per cent minimum required.
The company's trailing twelve-month debt/equity ratio of 0.00 per cent is excellent, according to the Motley Fool methodology, as it indicates that the company does not need to borrow money in order to grow.
Click here for a complete breakdown of Validea's investing guru report.
Globe app users click here.
Read other research reports here.